510(k) Approval for Silver Polyurethane



For Immediate Release

10 August 2009

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

510(k) Approval for Silver Polyurethane (PU) Anti–bacterial Foam Dressings 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it has received 510(k) approval from the Food and Drug Administration (FDA) to market its newly developed silver PU anti–bacterial foam dressings in the US.

AMS developed the dressings by combining silver, which is widely recognised as a safe and effective anti-microbial agent, with foam from Corpura, the company in which AMS acquired 49.4% ownership of in May 2008. Foam is one of the largest and fastest growing segments of the $3.2 billion advanced woundcare market and is an ideal material for the treatment of medium to high exudate chronic wounds.  This 510(k) approval builds upon other approvals AMS has for products including silver.

These silver PU anti–bacterial foam dressings have gained 510(k) approval for the management of light to moderate exuding, partial to full thickness wounds including pressure sores, diabetic ulcers, leg ulcers, graft and donor sites, lacerations and abrasions, first and second degree burns, trauma wounds and post-operative surgical wounds.

AMS is working to identify a suitable partner to commercialise the launch of these products in the US. Approval for these products will take longer in Europe than in the US and the full benefits of commercialisation will be realised when European approval has been obtained.

Commenting on this announcement, Dr Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

“This 510(k) approval for silver PU anti–bacterial foam dressings extends the AMS portfolio of materials incorporating silver and underlines the benefits of our acquisition last year of an interest in Corpura.  This approval marks the first success of an innovative  development  programme to combine  actives  into Corpura’s polyurethane foam technology and we look forward to further progress from this programme.“

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: +44 (0) 1606 545508
Buchanan Communications
Mark Court / Stasa Filiplic	Tel: +44 (0) 20 7466 5000
Investec Bank plc	Tel: +44 (0) 20 7597 5970
Richard Jones / Tim Pratelli

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle.  AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

END

MSCEAPPEFFPNEEE